Eurofins Scientific SA completed the acquisition of Boston Heart Diagnostics Corporation from Bain Capital Venture Fund 2009, L.P., a fund of Bain Capital Ventures, Beacon Angels, LLC, Cherrystone Angel Group, Launchpad Venture Group, LLC and others.
January 31, 2015 at 04:00 am
Share
Eurofins Scientific SA (ENXTPA:ERF) signed a definitive agreement to acquire Boston Heart Diagnostics Corporation from Bain Capital Venture Fund 2009, L.P. , a fund of Bain Capital Ventures, Beacon Angels, LLC, Cherrystone Angel Group, Launchpad Venture Group, LLC and others for $200 million on December 8, 2014. The purchase price is subject to post-closing adjustments and the consideration to be paid includes $140 million plus an earn-out payment of approximately $60 million upon achievement of certain milestones. Upon closing of the transaction Boston Heart Diagnostics Corporation will continue to be known as Boston Heart Diagnostics Corporation. The transaction includes retaining Boston Heart's high quality workforce of nearly 350 employees. The transaction is subject to applicable regulatory approvals and customary closing conditions and is expected to close in next 60 days. Eurofins Scientific expects the transaction to be accretive for its stockholders. Steven J. Dickinson and Adam J. Duerr of Fredrikson & Byron P.A. acted as legal advisor to Eurofins Scientific SA.
As announced on December 31, 2014, the transaction received approval from the Federal Trade Commission. Lazard acted as the financial advisor to Boston Heart Diagnostics Corporation.
Eurofins Scientific SA (ENXTPA:ERF) completed the acquisition of Boston Heart Diagnostics Corporation from Bain Capital Venture Fund 2009, L.P., a fund of Bain Capital Ventures, Beacon Angels, LLC, Cherrystone Angel Group, Launchpad Venture Group, LLC and others on January 31, 2015. The deal was closed following review and approval from relevant regulatory bodies.
Eurofins Scientific SE is one of the world's leading providers of bio-analytical services. The group's services are intended to validate the safety, authenticity, origin, identity, and purity of biological substances contained in the environment (water, air, soil, etc.) and in food, pharmaceutical, cosmetic, and hygiene products.
At the end of 2023, Eurofins Scientific SE owned a portfolio of over 200,000 analytical methods and had 900 laboratories located throughout the world.
Net sales are distributed geographically as follows: Europe (50.7%), North America (38.5%) and other (10.8%).
Eurofins Scientific SA completed the acquisition of Boston Heart Diagnostics Corporation from Bain Capital Venture Fund 2009, L.P., a fund of Bain Capital Ventures, Beacon Angels, LLC, Cherrystone Angel Group, Launchpad Venture Group, LLC and others.
EUROFINS SCIENTIFIC SE 
